In honor of Labor Day, here are three Houston innovators who probably aren't taking the day off. Courtesy photos

It may be Labor Day, but some of the hardest working Houston innovators are probably still checking their email on their phones from the pool.

Here are this week's innovators to know around town.

Marie Myers, CFO of UiPath

Marie Myers is the CFO of UiPath. Courtesy of UiPath

Marie Myers is a self-proclaimed Houstonian, avid bike rider, and robotics nerd — for lack of a better word. She's had a 20-year career in tech — most roles based right here in town — and throughout her whole experience, robotics process automation has been the most exciting technology she's gotten to work with.

UiPath just opened an office in Houston earlier this year, and Myers serves the company as CFO. She first worked with UiPath on the client side of things, and the technology awed her. She says she jumped at the opportunity to join the organization.

"When I think about RPA, the world lights up for me," she says. "It's truly transformative."

Click here to read more about the company.

Marco Bo Hansen, chief customer officer at Sani nudge and his executive team

Marco Bo Hansen, right, the chief customer officer at Sani nudge. Courtesy of TMCx

The Sani nudge executives may not be from Houston, but we give the Denmark-based company a pass for all its success coming out of the Texas Medical Center's accelerator program earlier this year. Sani nudge is a medical device company that can better track and encourage hand sanitation. The company is headed to California after being selected for a prestigious program with the Mistletoe Foundation.

Dr. Marco Bo Hansen is the chief customer officer and says that he'll be vigilantly advocating that his Sani nudge colleagues and the Mistletoe researchers keep hospital patients and staff in mind as Sani nudge moves forward with its innovations.

"We have to make sure that our solutions always generate value to the end users and can easily be used by the clinicians, infection preventionists, and hospital managers," he says.

Click here to read more about the company.

Ashley Gilmore, CEO and co-founder of Tracts.co

When Ashley Gilmore was studying law — specifically for the purposes of going into oil and gas — it amazed him how non-digitized the industry was, especially the mineral buying process. Gilmore figured out a way how to use tech to make the process way easier — and cheaper.

Now, his company, Tracts, has a new land group that's growing at a revenue rate of 30 percent month to month. With more and more clients, Tracts engages more data. And, with more and more data, the product increases in value for his customers.

"For some of our clients, Tracts is now existential for their business," Gilmore says. "In other words, they wouldn't be able to operate on their current business model without Tracts."

Click here to read more about the company.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.